Switch theme
Sign up to access all valuation multiples
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
1988
96
LTM Revenue $50.3M
LTM EBITDA $3.0M
$335M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Delcath Systems has a last 12-month revenue of $50.3M and a last 12-month EBITDA of $3.0M.
In the most recent fiscal year, Delcath Systems achieved revenue of $37.2M and an EBITDA of -$12.2M.
Delcath Systems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Delcath Systems valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $37.2M | XXX | XXX | XXX |
| Gross Profit | $2.0M | $1.4M | XXX | XXX | XXX |
| Gross Margin | 98% | 4% | XXX | XXX | XXX |
| EBITDA | -$46.1M | -$12.2M | XXX | XXX | XXX |
| EBITDA Margin | -2233% | -33% | XXX | XXX | XXX |
| Net Profit | -$36.5M | -$47.7M | XXX | XXX | XXX |
| Net Margin | -1768% | -128% | XXX | XXX | XXX |
| Net Debt | $8.0M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Delcath Systems's stock price is $12.
Delcath Systems has current market cap of $387M, and EV of $335M.
See Delcath Systems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $387M | XXX | XXX | XXX | XXX | $-0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Delcath Systems has market cap of $387M and EV of $335M.
Delcath Systems's trades at 6.7x LTM EV/Revenue multiple, and 112.5x LTM EBITDA.
Analysts estimate Delcath Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Delcath Systems and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $335M | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | -27.5x | XXX | XXX | XXX |
| P/E | -14.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDelcath Systems's NTM/LTM revenue growth is 89%
Delcath Systems's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Delcath Systems's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Delcath Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Delcath Systems and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1702% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -33% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -74% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 57% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 117% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Delcath Systems acquired XXX companies to date.
Last acquisition by Delcath Systems was XXXXXXXX, XXXXX XXXXX XXXXXX . Delcath Systems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Delcath Systems founded? | Delcath Systems was founded in 1988. |
| Where is Delcath Systems headquartered? | Delcath Systems is headquartered in United States of America. |
| How many employees does Delcath Systems have? | As of today, Delcath Systems has 96 employees. |
| Who is the CEO of Delcath Systems? | Delcath Systems's CEO is Mr. Gerard J. Michel. |
| Is Delcath Systems publicy listed? | Yes, Delcath Systems is a public company listed on NAS. |
| What is the stock symbol of Delcath Systems? | Delcath Systems trades under DCTH ticker. |
| When did Delcath Systems go public? | Delcath Systems went public in 2000. |
| Who are competitors of Delcath Systems? | Similar companies to Delcath Systems include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Delcath Systems? | Delcath Systems's current market cap is $387M |
| What is the current revenue of Delcath Systems? | Delcath Systems's last 12-month revenue is $50.3M. |
| What is the current EBITDA of Delcath Systems? | Delcath Systems's last 12-month EBITDA is $3.0M. |
| What is the current EV/Revenue multiple of Delcath Systems? | Current revenue multiple of Delcath Systems is 6.7x. |
| What is the current EV/EBITDA multiple of Delcath Systems? | Current EBITDA multiple of Delcath Systems is 112.5x. |
| What is the current revenue growth of Delcath Systems? | Delcath Systems revenue growth between 2023 and 2024 was 1702%. |
| Is Delcath Systems profitable? | Yes, Delcath Systems is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
